Conference Roundup

Aurinia To Present Supportive AURORA 2 Continuation Study Interim Analysis Demonstrating Long-Term Safety & Efficacy of LUPKYNIS (voclosporin) in Subjects with Lupus Nephritis

Aurinia Pharmaceuticals Inc (Aurinia or the Company) announced today that a supportive interim analysis of its AURORA 2 continuation study will be presented at the upcoming European Alliance of Associations for Rheumatology (EULAR) 2021 Congress June 2-5, 2021. Subjects who completed one year of treatment in Aurinia’s Phase 3 AURORA...